PharmaCorp Rx (PCRX) Planet MicroCap Showcase: Toronto 2026 summary
Event summary combining transcript, slides, and related documents.
Planet MicroCap Showcase: Toronto 2026 summary
8 Nov, 2026Acquisition strategy and pipeline
PharmaChoice alliance provides exclusive ROFRs on 1,150 stores; McKesson collaboration adds opportunities across IDA, Guardian and Remedy'sRx when McKesson does not pursue a store.
Management cited access to 3,000+ stores across the networks, with 30-50 PharmaChoice and 50-80 McKesson locations changing hands annually; banner-agnostic deal selection.
17 locations in the portfolio; an eight-store East Coast acquisition closed for CAD 24 million in July and is being integrated; two LOIs represent four stores.
Target acquisitions with at least CAD 2 million revenue and CAD 350,000 normalized EBITDA; weighted-average purchase multiple is 6x normalized EBITDA.
Acquisition diligence and growth
Evaluate each deal on normalized economics, prescription trends, staffing and managing-pharmacist coverage; willing to walk away from stores that cannot be staffed.
Project cumulative normalized EBITDA gains of 7.5%-15% over the first three years of ownership; management clarified this is cumulative, not annual CAGR.
Value creation includes purchasing efficiencies, network programs, expanded pharmacist services and automation; one purchasing change added CAD 80,000 in store profitability in one year.
Two smaller pharmacies were acquired and folded into existing stores in the prior year; one example combined a 10,000-prescription store with a 70,000-prescription location.
Acquired stores remain under their existing banners to preserve customer and staff continuity; planned store improvements can include rebranding, automation and expansion, including a planned doubling of one store early next year.
Ownership model and cash generation
Co-ownership loans let pharmacists buy in alongside the operator; 16 of 17 stores are expected to have a co-owner, including two where sellers retained 10% and 25% stakes.
CIBC acquisition term loan was initially CAD 17.5 million and upsized to CAD 27.5 million through an accordion; management cited ample capacity for current LOIs.
Target leverage is 2.0-2.5x as a high-water mark; funding options may include the market when conditions are attractive, alongside scaling debt for individual deals.
Maintenance CapEx is 20-40 bps of sales and EBITDA-to-free-cash-flow conversion exceeds 70%; a CAD 300,000 automation robot had a stated payback of 2.5 years.
Latest events from PharmaCorp Rx
- Exclusive acquisition pipeline and integration drive scalable growth in Canadian pharmacy.PCRX
Investor presentation - Revenue up 75.8% and net income positive as acquisitions boost pharmacy network to 16 stores.PCRX
Q2 2026 - Exclusive acquisition rights and integration drive scalable pharmacy growth in Canada.PCRX
Investor presentation - Q1 2026 revenue jumped 79.4% year-over-year, driven by acquisitions and organic growth.PCRX
Q1 2026 - Revenue up 75% and gross profit up 78% in Q4 2025, with strong M&A-driven growth.PCRX
Q4 2025 - Exclusive acquisition rights and integration drive scalable pharmacy growth in Canada.PCRX
Investor presentation - Pharmacy roll-up firm leverages exclusive alliances and capital to drive steady national expansion.PCRX
2026 Bloom Burton & Co. Healthcare Investor Conference - Q3 adjusted EBITDA and sales rose, with new capital and acquisitions fueling national expansion.PCRX
Q3 2025 - First profitable quarter with $254,000 net income and plans to acquire four pharmacies for $12.5M.PCRX
Q1 2025